Duquesne
Duquesne is a Series A to Series B stage investment firm. It has made 4 investments. Average disclosed round size is $38.5M (across 6 rounds with reported amounts).
Portfolio
4
Fund Size
—
Top Stage
Unknown
Last 12 Mo
0
Team
SM
Sue Meng
Partner and Managing Director
SM
Sue Meng
Partner and Managing Director
KW
Kevin Warsh
Partner and Advisor
MR
Matthew Rozyczka
Chief Investment Officer
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
6 investments
| Company | Round | Amount | Date |
|---|---|---|---|
| RRatio Therapeutics Inc. | Series B | $50M | Jan 2024 |
| RRatio Therapeutics Inc. | Series A | $20M | Feb 2023 |
 Ratio | Series A | $20M | Feb 2023 |
| RReplidyne | Unknown | $62M | Sep 2005 |
| RReplidyne | Unknown | $62M | Jan 2005 |
 Ledgebrook | Series B | $17M | — |
Top Co-Investors
Schusterman Family Investments3 shared
Morgenthaler Ventures2 shared
Catalio Capital Management2 shared
Duquesne Family Office2 shared
Sequel1 shared
PagsGroup1 shared
Bristol Myers Squibb1 shared
Western Technology Investment1 shared
Stephens Group1 shared
American Family Ventures1 shared
Brand Foundry Ventures1 shared
Stonks1 shared
Last updated: 27 September 2026